Sign inCreate account

Report workspace tools

NCT06889857ACTIVE_NOT_RECRUITINGanonymous

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

Sponsor

Source record

Hitonowa Medical

Phase

Source record

EARLY_PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

The study drug is SHED-CM manufactured by U-Factor

Indication / condition

AI-normalized

Amyotrophic Lateral Sclerosis

Intervention

Source record

The study drug is SHED-CM manufactured by U-Factor

Source & freshness

Source record

NCT ID

NCT06889857

Original source

ClinicalTrials.gov

Source last updated

Sep 15, 2025

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06889857

Title

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

Sponsor

Hitonowa Medical

Status

ACTIVE_NOT_RECRUITING

Phase

EARLY_PHASE1

Condition raw

Amyotrophic Lateral Sclerosis

Condition normalized

Amyotrophic Lateral Sclerosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

The study drug is SHED-CM manufactured by U-Factor

Target normalized

The study drug is SHED-CM manufactured by U-Factor

Interventions

The study drug is SHED-CM manufactured by U-Factor

Public preview

Source record

This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Safety and Efficacy of Intravenous Administration of SHED-CM for ALS

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06889857

Status

ACTIVE_NOT_RECRUITING

Phase

EARLY_PHASE1

Sponsor

Hitonowa Medical

Executive brief

Investment-Ready Snapshot

This study evaluates the safety and efficacy of Stem Cell from Human Exfoliated Deciduous teeth Conditioned Media (SHED-CM) in patients with Amyotrophic Lateral Sclerosis (ALS), using the Japanese version of the revised ALS Functional Rating Scale (ALSFRS-R) as an indicator.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 15, 2025
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06889857

Indication

Amyotrophic Lateral Sclerosis

Modality

small molecule

Target

The study drug is SHED-CM manufactured by U-Factor

Intervention

The study drug is SHED-CM manufactured by U-Factor

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.